JP2017504649A - 腎障害及び脂肪性肝障害の治療並びに予防のための方法 - Google Patents

腎障害及び脂肪性肝障害の治療並びに予防のための方法 Download PDF

Info

Publication number
JP2017504649A
JP2017504649A JP2016549388A JP2016549388A JP2017504649A JP 2017504649 A JP2017504649 A JP 2017504649A JP 2016549388 A JP2016549388 A JP 2016549388A JP 2016549388 A JP2016549388 A JP 2016549388A JP 2017504649 A JP2017504649 A JP 2017504649A
Authority
JP
Japan
Prior art keywords
nonalcoholic
subject
canagliflozin
fatty liver
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016549388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504649A5 (enExample
Inventor
エス． ウシスキン，キース
エス． ウシスキン，キース
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017504649(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2017504649A publication Critical patent/JP2017504649A/ja
Publication of JP2017504649A5 publication Critical patent/JP2017504649A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016549388A 2014-01-31 2015-01-30 腎障害及び脂肪性肝障害の治療並びに予防のための方法 Withdrawn JP2017504649A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461934003P 2014-01-31 2014-01-31
US61/934,003 2014-01-31
US201461948882P 2014-03-06 2014-03-06
US61/948,882 2014-03-06
PCT/US2015/013644 WO2015116880A1 (en) 2014-01-31 2015-01-30 Methods for the treatment and prevention of renal disorders and fatty liver disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020005106A Division JP2020090511A (ja) 2014-01-31 2020-01-16 腎障害及び脂肪性肝障害の治療並びに予防のための方法

Publications (2)

Publication Number Publication Date
JP2017504649A true JP2017504649A (ja) 2017-02-09
JP2017504649A5 JP2017504649A5 (enExample) 2018-03-08

Family

ID=52544570

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016549388A Withdrawn JP2017504649A (ja) 2014-01-31 2015-01-30 腎障害及び脂肪性肝障害の治療並びに予防のための方法
JP2020005106A Pending JP2020090511A (ja) 2014-01-31 2020-01-16 腎障害及び脂肪性肝障害の治療並びに予防のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020005106A Pending JP2020090511A (ja) 2014-01-31 2020-01-16 腎障害及び脂肪性肝障害の治療並びに予防のための方法

Country Status (11)

Country Link
US (3) US20160339047A1 (enExample)
EP (1) EP3099328A1 (enExample)
JP (2) JP2017504649A (enExample)
KR (1) KR20160107344A (enExample)
CN (3) CN113144204A (enExample)
AU (2) AU2015210898A1 (enExample)
CA (1) CA2938406A1 (enExample)
EA (1) EA201691555A1 (enExample)
IL (1) IL246779A0 (enExample)
MX (1) MX2016010011A (enExample)
WO (1) WO2015116880A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523408A (ja) * 2017-06-12 2020-08-06 ヤンセン ファーマシューティカ エヌ．ベー． ２型糖尿病の患者における心血管イベントの低減又は予防方法
JP2022526914A (ja) * 2019-03-26 2022-05-27 ヤンセン ファーマシューティカ エヌ．ベー． 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018113437A (ru) * 2015-09-16 2019-10-17 Тобира Терапьютикс, Инк. Комбинированная терапия с использованием ценикривирока для лечения фиброза
ES2979120T3 (es) * 2015-11-06 2024-09-24 Gelteq Ltd Método y producto para evaluar la respuesta a una carga oral de glucosa
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
ES3035734T3 (en) 2017-11-30 2025-09-08 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
CN110051851A (zh) * 2019-05-31 2019-07-26 江苏苏中药业集团股份有限公司 一种钠-葡萄糖共转运蛋白-2抑制剂与黄蜀葵花提取物的组合
KR20230057388A (ko) * 2020-08-17 2023-04-28 티엔진 크레아트론 바이오테크놀로지 컴파니 리미티드 Sglt-2 억제제와 안지오텐신 수용체 길항제의 조성물 및 이의 용도
IL301831A (en) * 2020-10-30 2023-06-01 Resverlogix Corp Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
WO2022104621A1 (zh) * 2020-11-19 2022-05-27 北京睿创康泰医药研究院有限公司 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途
JP2024094532A (ja) 2022-12-28 2024-07-10 キヤノン株式会社 撮像設定装置および撮像装置
KR20240126452A (ko) * 2023-02-10 2024-08-21 가천대학교 산학협력단 칸데사르탄 또는 아질사르탄을 포함하는 조성물의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511602A (ja) * 2006-12-04 2010-04-15 田辺三菱製薬株式会社 １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼン１／２水和物の結晶形
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
EP2514756B1 (en) 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
WO2008113095A1 (en) * 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2756779C (en) * 2009-03-26 2019-10-29 Ajay Gupta Compositions and methods for treatment of renal disease
KR101890959B1 (ko) * 2010-11-04 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
US8946224B2 (en) * 2010-11-11 2015-02-03 Redx Pharma Limited Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511602A (ja) * 2006-12-04 2010-04-15 田辺三菱製薬株式会社 １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼン１／２水和物の結晶形
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIABETES. OBES. METAB., 2013, VOL.15, NO.5, PP.463-473, JPN6018039459, ISSN: 0004113557 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523408A (ja) * 2017-06-12 2020-08-06 ヤンセン ファーマシューティカ エヌ．ベー． ２型糖尿病の患者における心血管イベントの低減又は予防方法
JP2022526914A (ja) * 2019-03-26 2022-05-27 ヤンセン ファーマシューティカ エヌ．ベー． 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン

Also Published As

Publication number Publication date
EP3099328A1 (en) 2016-12-07
CN113144204A (zh) 2021-07-23
WO2015116880A1 (en) 2015-08-06
CN113082021A (zh) 2021-07-09
CA2938406A1 (en) 2015-08-06
MX2016010011A (es) 2016-10-07
EA201691555A1 (ru) 2017-01-30
JP2020090511A (ja) 2020-06-11
AU2020281039A1 (en) 2021-01-07
CN105939728A (zh) 2016-09-14
KR20160107344A (ko) 2016-09-13
IL246779A0 (en) 2016-08-31
US20210121492A1 (en) 2021-04-29
AU2015210898A1 (en) 2016-07-28
US20180344756A1 (en) 2018-12-06
US20160339047A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
US20210121492A1 (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
AU2022246392B2 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
US12263153B2 (en) Pharmaceutical composition, methods for treating and uses thereof
HK40056944A (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
HK40055858A (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
HK1224940A1 (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders
EA042969B1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200116

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200124

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200326